VLS-1272

VLS-1272 (Compound 22) is an orally active KIF18A inhibitor that binds to the KIF18A-microtubule complex in an ATP-noncompetitive manner (IC50 = 41 nM), blocking its ATPase activity and inhibiting microtubule translocation. This leads to abnormal accumulation of KIF18A at spindle poles, disrupting chromosome alignment and inducing mitotic arrest and apoptosis in CINHigh tumor cells (e.g., ovarian cancer OVCAR-3, breast cancer JIMT-1) . VLS-1272 is a promising candidate for anti-tumor research[1][2].

Product Specifications

CAS Number

[2914878-00-3]

Product Name Alternative

KIF18A-IN-7

UNSPSC

12352005

Target

Apoptosis; Kinesin; Microtubule/Tubulin

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/kif18a-in-7.html

Concentration

10mM

Purity

99.63

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(C1=CC(C(N2CC3(CCC4(CC4)CC3)C5=CC(NS(C)(=O)=O)=CC=C52)=O)=CC=C1)(NC(C)(C)C)=O

Molecular Formula

C27H35N3O5S2

Molecular Weight

545.71

References & Citations

[1]COGAN, et al. SPIRO INDOLINE INHIBITORS OF KIF18A. Patent WO2023028564.|[2]Phillips AF, et al. Targeting chromosomally unstable tumors with a selective KIF18A inhibitor. Nat Commun. 2025 Jan 2;16 (1) :307.